By Vinay Prasad, MD MPH
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from Oregon Health & Science University. Tweet your feedback to @Plenary_Session or e-mail firstname.lastname@example.org.
||Explicit1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints||Special episode! We discuss the recent correspond…||9/20/2018||Free||View in iTunes|
||Explicit1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds||In this episode we discuss hyperprolific authors …||9/14/2018||Free||View in iTunes|
||Explicit1.07 Adjuvant Sunitinib in RCC, future of EBM with John Mandrola||In this episode we discuss the USA FDA's recent a…||9/11/2018||Free||View in iTunes|
||Explicit1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority||In this episode we break down the RELEVANCE trial…||9/7/2018||Free||View in iTunes|
||Explicit1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity||In this episode we cover the cost and efficacy of…||9/5/2018||Free||View in iTunes|
||Explicit1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser||This week's episode is on nutritional epidemiolog…||8/30/2018||Free||View in iTunes|
||Explicit1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross||We're moving to our new format. We begin with a m…||8/21/2018||Free||View in iTunes|
||Explicit1.02: HemOnc Fellowship and Hype in Cancer Medicine with Dr. Jeremy Cetnar||In episode 2, we discuss the fellowship program a…||8/16/2018||Free||View in iTunes|
||Explicit1.01: Introduction and Dr. Adam Obley||Join us for an introduction to who we are and wha…||8/14/2018||Free||View in iTunes|
Informative, Clear, and Enjoyable
Dr. Prasad gives important voice to the need for unbiased clinical trials and research reporting to ensure that patients' benefit remains the first priority in modern oncological research and practice, ie. living longer and living better.
Awesome discussions of latest oncology news
Dr. Prasad’s analysis of the Lenvatinib trial was so satisfying!
Dr. Prasad is very knowledgeable and I find his opinions to be very relevant and timely in the current healthcare atmosphere. I appreciate his passionate for raising the bar!